Buffalo Business & Estate Services Ltd. Buys Shares of 25,447 Johnson & Johnson $JNJ

Buffalo Business & Estate Services Ltd. bought a new stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 25,447 shares of the company’s stock, valued at approximately $5,266,000. Johnson & Johnson accounts for 0.8% of Buffalo Business & Estate Services Ltd.’s investment portfolio, making the stock its 24th biggest position.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson in the third quarter valued at $26,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the third quarter valued at $28,000. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $27,000. Semmax Financial Advisors Inc. raised its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares during the period. Finally, Turning Point Benefit Group Inc. purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $41,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Big analyst bullishness — Citigroup raised its price target to $285 and maintained a Buy, signaling a material upside to consensus; Guggenheim and TD Cowen also have Buy calls and lifted targets, supporting near-term demand. Citigroup raises price target to $285
• Positive Sentiment: New/maintained buy coverage from TD Cowen and supportive analyst commentary highlight J&J’s diversified pipeline and attractive risk/reward into earnings. TD Cowen / TipRanks coverage
• Positive Sentiment: Regulatory / product catalyst — J&J launched its next‑gen Varipulse Pro PFA catheter in Europe (CE mark), which could support device revenue growth in electrophysiology. Varipulse Pro launch in Europe
• Positive Sentiment: Specialty therapy wins — permanent U.S. reimbursement code for bladder cancer therapy INLEXZO and distribution deals (e.g., SIRTURO in Japan) reduce commercialization risk and boost revenue visibility in niche franchises. Johnson & Johnson updates key specialty therapies
• Neutral Sentiment: Media/analyst pieces are bullish ahead of Q1 — Barron’s and other outlets recommend buying into the earnings run-up, which supports momentum but also raises expectations risk. Barron’s: Buy ahead of earnings
• Neutral Sentiment: Mixed market commentary — coverage noting the stock “increases yet falls behind the market” and inclusion on low‑volatility/blue‑chip lists boost interest but are not direct fundamental drivers. Zacks: Increases yet falls behind market

Analyst Ratings Changes

Several equities research analysts recently issued reports on JNJ shares. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Rothschild & Co Redburn boosted their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a report on Thursday, February 19th. Loop Capital set a $220.00 price objective on Johnson & Johnson in a report on Tuesday, January 27th. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, March 5th. Finally, Argus upped their price target on Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $237.57.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 over the last ninety days. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Up 1.1%

NYSE:JNJ opened at $241.01 on Thursday. The stock has a 50-day simple moving average of $240.79 and a 200-day simple moving average of $214.35. The stock has a market cap of $580.51 billion, a P/E ratio of 21.81, a P/E/G ratio of 2.41 and a beta of 0.34. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The firm had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.